Kidney trouble may skew chemo safety test – new study aims to fix that
NCT ID NCT07124403
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looks at whether kidney problems interfere with a common blood test used to check how well patients break down certain chemotherapy drugs (fluoropyrimidines). Researchers will measure DPD enzyme activity in about 742 people with breast or digestive cancer, kidney failure, or both. The goal is to make sure the test correctly identifies patients at risk of severe side effects, so doses can be adjusted safely.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
blood sampling
What this could lead to
If successful, this could help doctors personalize chemotherapy doses for patients with kidney disease, reducing severe side effects.
What could go wrong
This is an observational study, not a treatment trial. It may not change practice immediately, and results might not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.